Se rendre au contenu

Evaluate the fibrotic potentials of your drugs with our preclinical and clinical tools

We are designing and proposing novel game changing molecular tools to evaluate the fibrotic potentials of drugs for preclinical studies and patient samples.  

Discover more

Building conditions for the development of efficient drugs against fibrosis and cancers

We use the current knowledge of the actual implication of fibrosis and excessive matrix synthesis in the failure of anti-cancer drug to design and develop novel products allowing the monitoring and evaluation of the fibrosis and resistance-inducing potentials of drug candidates in preclinical studies ensuring success in clinical trials.

Contact Us

Creating new opportunities of efficient preclinical drug discovery that ensure success in clinical trials of cancer treatment.



Fibrosis is at the core center of the failure of drug candidates for cancer treatment in clinical trials as well as after approval due to the induced resistance. We commit to develop and provide novel next-generation tools for monitoring the premise indications of fibrosis as well as therapeutic approaches based on normalizing and preventing the neosynthesis of extracellular matrix proteins involved in fibrotic scars. We aim to substantially decrease the cost of drug development by providing tools allowing the selection of effective drug candidates with low induction of resistance.

Developing strategies to mitigate all resistance to drugs in cancer therapy.

Designed and developed by experts in fibrosis, extracellular matrix and cancer research to bring biotechnological innovations into clinical practice